US EditionPublished • loading... • Updated
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
QureBio's Q-1802 plus XELOX shows 70% objective response rate and 11.3 months median progression-free survival in advanced gastric cancer, supporting phase III trial dose.
- QureBio Ltd. revealed Phase Ib/II data via abstract #537934, enrolling 62 eligible patients treated with Q-1802 plus XELOX, with no DLTs observed.
- Chinese CDE recently approved the phase III trial after Dr. Gong et al. reported on enrollment and safety data for Q-1802 10 mg/kg plus XELOX in advanced gastric cancer, supporting further development.
- In the 60 efficacy‑evaluable patients, ORR was 70.0%, DCR 98.3% and mPFS 11.3 months; in the 10 mg/kg cohort, ORR rose to 81.8% in the PD‑L1 CPS≥5 subgroup with mPFS 12.2 months.
- Safety data show permanent discontinuation 6.5% due to TEAEs, no treatment‑related death, most common Grade 3 thrombocytopenia 8.1%, neutropenia 6.5%, and anemia/WBC decrease/hypokalemia 4.8% each.
- Q-1802's mechanism involves killing tumors via ADCC, ADCP and adaptive immunity with DC and T cells; QureBio Ltd. and partners describe it as highly selective with a favorable safety profile for Claudin18.2‑positive solid tumors.
Insights by Ground AI
46 Articles
46 Articles
Bennington Banner+45 Reposted by 45 other sources
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission about…
Coverage Details
Total News Sources46
Leaning Left6Leaning Right6Center15Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
